Virus Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Virus Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bird Flu
Afid Therapeutics Obtains Positive Evaluation of its Triple Mode Viral Sequestration Agents
April 10th, 2007
Afid Therapeutics, Inc. announced that it received positive results on the ability of its new triple mode viral sequestration agents to block viral infections of mammalian cells. The audited results were obtained from a specialized, independent third party testing organization. The new viral sequestrating agents are designed to bind and inactivate viruses by 3 critical mechanisms thus blocking infection. They are aimed at viruses responsible for common causes of influenza in addition to SARS, bird flu and other avian influenzas. "Carbohydrate interactions are critical to the infection process in these systems. The technology capitalizes on the companies' rich carbohydrate chemistry...
Source: Virus Weekly (2007-04-10)
|
|
Advertisement |
|
|
|
